Name | (2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl]propanoic acid |
---|---|
Synonyms |
UNII-41T4OAG59U
R-1439 Aleglitazar |
Description | Aleglitazar(R1439; RO-0728804) is a new dual PPAR-α/γ agonist with IC50 of 2.8 nM/4.6 nM.IC50 Value: 2.8 nM(PPAR-α); 4.6 nM(PPAR-γ)Target: PPARα/γAleglitazar (R1439) is a dual peroxisome proliferator-activated receptor (PPAR) agonist, with affinity to PPARα and PPARγ. Aleglitazar is being developed for the treatment of type II diabetes; It is currently in phase III clinical trials. In preliminary clinical studies, Aleglitazar has been demonstrated to improve hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus. Aleglitazar has beneficial effects on both lipid and glucose parameters and may have a therapeutic role in modifying cardiovascular risk factors and improving glycemic control in patients with T2DM. Aleglitazar combines the lipid benefits of fibrates and the insulin-sensitizing benefits of thiazolidinediones. |
---|---|
Related Catalog | |
Target |
PPARγ:19 nM (IC50) PPARα:38 nM (IC50) |
References |
Density | 1.29 |
---|---|
Boiling Point | 665.151ºC at 760 mmHg |
Molecular Formula | C24H23NO5S |
Molecular Weight | 437.50800 |
Flash Point | 356.071ºC |
Exact Mass | 437.13000 |
PSA | 110.03000 |
LogP | 5.12830 |
Index of Refraction | 1.627 |
Storage condition | 2-8℃ |
~99% 475479-34-6 |
Literature: US2005/70714 A1, ; Page/Page column 10 ; |
~72% 475479-34-6 |
Literature: US2010/249428 A1, ; Page/Page column 10 ; |
~% 475479-34-6 |
Literature: WO2013/181384 A1, ; Paragraph 0069; 0070; 0071; 0072 ; |
~% 475479-34-6 |
Literature: US2003/55265 A1, ; |